GRADE evidence profiles 65Other adjunctive treatments: Arginine-glycine-aspartic acid (RGD) peptide matrix

Quality assessmentSummary of findings
No of patientsEffectQuality
No of studiesDesignLimitationsInconsistencyIndirectnessImprecisionOther considerationsDalteparin (injection)controlRelative
(95% CI)
Complete wound healing (6 months) (follow-up 6 months)
RCTserious1no seriousno seriousserious2none14/40 (35.0%)2/25 (8.0%)RR 4.36 (1.08 to 17.65)
NNTB = 4 (2 to 16)
27 more per 100 (from 1 fewer to 100 more)LOW

[S] = Steed el al. (1995). RGD peptide matrix + standard care vs saline gauze + standard care only (control). Standard care = debridement, dressing.


Allocation concealment unclear.


Total no. of event <300.

From: Appendix E, Full GRADE evidence profiles

Cover of Diabetic Foot Problems
Diabetic Foot Problems: Inpatient Management of Diabetic Foot Problems.
NICE Clinical Guidelines, No. 119.
Centre for Clinical Practice at NICE (UK).
Copyright © 2011, National Institute for Health and Clinical Excellence.

All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.